Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by houbahopon May 03, 2021 7:00am
117 Views
Post# 33112530

RE:A case for voting out Gary Littlejohn

RE:A case for voting out Gary LittlejohnIn all cases, it simply resumes to one factor going into the proxy vote.

If you feel, after this interaction with Theratechnologies' management, they are simply trying to buy time to keep the Board intact for 2021-22, VS having a proactive action plan to deal with the issues concerning aligning their interests with shareholders,

YOU BETTER VOTE ACCORDINGLY AND SEND A STRONG MESSAGE TO THE BOD IT CAN NO LONGER BE BUSINESS AS USUAL!

Otherwise, you are screwing yourself.

From my perspective, I see major changes to be done at the corporate governance level. This long lasting problem at Theratechnologies brought the next problem: Massive dilution of existing shareholders. When trying to fix thing, you have to deal with the roots of the problem.

Good luck to all making the right decision, I'll be watching the results.


<< Previous
Bullboard Posts
Next >>